Shares of Editas Medicine (EDIT 4.67%) charged sharply higher this week, soaring as much as 41.6%, according to data from S&P Global Market Intelligence. By the time the market closed on Friday, the stock was still up 34.8%.The catalyst that vaulted the gene editing specialist higher was the company's quarterly report, which included a surprise announcement.Alignment with the FDAOn Wednesday, Editas Medicine released its fourth-quarter results, which were better than investors had hoped. The company generat ...

Editas Medicine, Inc. (EDIT) incurred a loss of 23 cents per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 52 cents. The company had reported a loss of 88 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $60 million in the reported quarter, up significantly from $6.5 million reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate o ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - CSO Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Joon Lee - Truist Securities Samantha Semenkow - Citi Brian Cheng - JPMorgan Greg Harrison - Bank of America Mani Foroohar - Leerink Max Skor - Morgan Stanley Gena Wang - Barclays Da ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.77%. A quarter ago, it was expected that this genome editing company would post a loss of $0.64 per share when it actually produced a loss of $0.55, delivering a surprise of 14.06%.Over the last four quarters, the compa ...

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024 Initiated enrollment in the adolescent cohort in the RUBY trial Entered into a license agreement providing Vertex Pharmaceuticals a non-exclusive license for Cas9 Strong financial position with operational r ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________ FORM 10-K __________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Nu ...

Shares of Editas Medicine (EDIT) have gained 0.7% over the past four weeks to close the last trading session at $8.15, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.67 indicates a potential upside of 80%.The average comprises 12 short-term price targets ranging from a low of $7 to a high of $27, with a standard deviation of $6.69. While the lowest estimate indicates a decl ...

Editas Medicine, Inc. (NASDAQ:EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 8:40 AM ET Company Participants Dr. Baisong Mei - Senior Vice President and Chief Medical Officer Conference Call Participants Jay Olson - Oppenheimer Jay Olson Hello everyone and welcome to Oppenheimer’s 34th Annual Healthcare Conference. I am Jay Olson, one of the biotech analysts at Oppenheimer and I want to thank you for joining us. It's my pleasure to welcome Editas to our conference, and i ...

Quite a few bigwigs in the biotech sector have reported results for the fourth quarter and the picture is ordinary. While results have been mixed, the outlook provided by most of these companies is encouraging, indicating bright prospects driven by new drug approvals and positive pipeline updates. The macroeconomic environment, however, remains uncertain and growth might be sluggish.Meanwhile, biotech companies are in the spotlight as pharma/biotech giants are now looking to bolster their product portfolios ...

Editas Medicine, Inc. (NASDAQ:EDIT) Guggenheim 6th Annual Biotechnology Conference February 7, 2024 9:30 AM ET Company Participants Gilmore O'Neill - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Debjit Chattopadhyay Good morning. Thank you for joining the Guggenheim Securities Healthcare team at our 6th Annual Conference. I'm Debjit and joining us from Editas Medicine is its President and CEO, Gilmore O'Neill. Thank you so much for your time Gilmore. And if we could start ...